|
CA3061086A1
|
|
Lipophilic active oral film formulation and method of making the same
|
|
WO2020051709A1
|
|
Method of treatment and device for the improved bio availability of montelukast, a leukotriene receptor antagonist
|
|
US2020138730A1
|
|
Lipophilic active oral film formulation and method of making the same
|
|
US2019231685A1
|
|
Antihistamine oral film dosage form and method of administrating same
|
|
US2020101008A1
|
|
Oral film formulation for modulating absorption profile
|
|
US2019133925A1
|
|
Method of treatment and device for the improved bioavailability of leukotriene receptor antagonists
|
|
CA3017526A1
|
|
Method of treatment and device for the improved bioavailability of leukotriene receptor antagonists
|
|
US2018360736A1
|
|
Film dosage form with extended release mucoadhesive particles
|
|
US2019000770A1
|
|
Loxapine film oral dosage form
|
|
CA3062704A1
|
|
Film dosage form with extended release mucoadhesive particles
|
|
US2018250240A1
|
|
Method of treatment and device for the improved bioavailability of leukotriene receptor antagonists
|
|
KR20190128637A
|
|
Therapeutic Methods and Apparatus for Improved Bioavailability of Leukotriene Receptor Antagonists
|
|
US2018110724A1
|
|
Film dosage form with multimodal and particle size distributions
|
|
AU2017344764A1
|
|
Device and method of treating conditions associated with neuroinflammation
|
|
US2017239172A1
|
|
Film dosage form with extended release mucoadhesive particles
|
|
US2017157119A1
|
|
Solid oral film dosage forms and methods for making same
|
|
US2017258710A1
|
|
Montelukast transmucosal film
|
|
US2017216220A1
|
|
Loxapine film oral dosage form
|
|
US2016243036A1
|
|
Film dosage forms containing amorphous active agents
|
|
US2016220480A1
|
|
Oral dosage film exhibiting enhanced mucosal penetration
|
